Top

Published in:

01-05-2013 | Neurology and Preclinical Neurological Studies - Original Article

Switch from selegiline to rasagiline is beneficial in patients with Parkinson’s disease

Authors: Thomas Müller, Josef A. Hoffmann, Walter Dimpfel, Christian Oehlwein

Published in: Journal of Neural Transmission | Issue 5/2013

Abstract

The objective of this study is to demonstrate that application of rasagiline instead of selegiline with concomitant determination of l-amphetamine and l-methamphetamine in plasma is safe and well tolerated and influences sleep, mood, and motor behavior in patients with Parkinson’s disease on a stable drug therapy. 30 patients, who took 7.5 mg selegiline daily for at least 3 months, were switched to 1 mg rasagiline. Then they were followed over an interval of 4 months. The remaining drug therapy remained stable. This changeover was safe and well tolerated. l-Amphetamine and l-methamphetamine only appeared during selegiline treatment. Motor behavior, motor complications, mood and sleep improved during rasagiline administration. Amphetamine-like derivatives of selegiline could contribute to sleep disturbances, which may be involved in worsening of mood. Motor behavior and motor complications probably became better due to the additional glutamate receptor antagonizing properties of rasagiline in this open label study.

Antonini G, Morino S, Fiorelli M, Fiorini M, Giubilei F (1997) Selegiline in the treatment of hypersomnolence in myotonic dystrophy: a pilot study. J Neurol Sci 147:167–169PubMedCrossRef

Bar-Am O, Weinreb O, Amit T, Youdim MB (2010) The neuroprotective mechanism of 1-(R)-aminoindan, the major metabolite of the anti-parkinsonian drug rasagiline. J Neurochem 112:1131–1137PubMedCrossRef

Brickenkamp R (2002) Test d₂: aufmerksamkeits-belastungs-test. Göttingen, Hogrefe Verlag

Brotchie J, Johnston TH, Visanji NP (2011) 1-Aminoindan, a main metabolite of rasagiline, enhances dopamine release and provides symptomatic benefit in an animal model of Parkinson’s disease. Parkinsonism Relat Disord 2007:102

Buysse DJ, Angst J, Gamma A, Ajdacic V, Eich D, Rossler W (2008) Prevalence, course, and comorbidity of insomnia and depression in young adults. Sleep 31:473–480PubMed

Chen JJ, Swope DM, Dashtipour K (2007) Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson’s disease. Clin Ther 29:1825–1849PubMedCrossRef

Dimpfel W, Hoffmann J (2011) Effects of rasagiline, its metabolite aminoindan and selegiline on glutamate receptor mediated signalling in the rat hippocampus slice in vitro. BMC Pharmacol 11:2PubMedCrossRef

Dusek P, Buskova J, Ruzicka E, Majerova V, Srp A, Jech R, Roth J, Sonka K (2010) Effects of ropinirole prolonged-release on sleep disturbances and daytime sleepiness in Parkinson disease. Clin Neuropharmacol 33:186–190PubMedCrossRef

Fernandez HH, Chen JJ (2007) Monamine oxidase inhibitors: current and emerging agents for Parkinson disease. Clin Neuropharmacol 30:150–168PubMedCrossRef

Garcia-Borreguero D, Schwarz C, Larrosa O, de la LY, de Garcia YJ (2003) L-DOPA-induced excessive daytime sleepiness in PD: a placebo-controlled case with MSLT assessment. Neurol 61:1008–1010CrossRef

Gregory AM, Buysse DJ, Willis TA, Rijsdijk FV, Maughan B, Rowe R, Cartwright S, Barclay NL, Eley TC (2011) Associations between sleep quality and anxiety and depression symptoms in a sample of young adult twins and siblings. J Psychosom Res 71:250–255PubMedCrossRef

Hauser RA, Auinger P, Parkinson Study Group (2011) Determination of minimal clinically important change in early and advanced Parkinson’s disease. Mov Disord 26:813–818CrossRef

He S, Grasing K (2006) L-methamphetamine and selective MAO inhibitors decrease morphine-reinforced and non-reinforced behavior in rats; insights towards selegiline’s mechanism of action. Pharmacol Biochem Behav 85:675–688PubMedCrossRef

Kahn-Greene ET, Killgore DB, Kamimori GH, Balkin TJ, Killgore WD (2007) The effects of sleep deprivation on symptoms of psychopathology in healthy adults. Sleep Med 8:215–221PubMedCrossRef

Killgore WD (2010) Effects of sleep deprivation on cognition. Prog Brain Res 185:105–129PubMedCrossRef

Kronstrand R, Ahlner J, Dizdar N, Larson G (2003) Quantitative analysis of desmethylselegiline, methamphetamine, and amphetamine in hair and plasma from Parkinson patients on long-term selegiline medication. J Anal Toxicol 27:135–141PubMed

Laine K, Anttila M, Huupponen R, Maki-Ikola O, Heinonen E (2000) Multiple-dose pharmacokinetics of selegiline and desmethylselegiline suggest saturable tissue binding. Clin Neuropharmacol 23:22–27PubMedCrossRef

Lecht S, Haroutiunian S, Hoffman A, Lazarovici P (2007) Rasagiline—a novel MAO B inhibitor in Parkinson’s disease therapy. Ther Clin Risk Manag 3:467–474PubMed

Mayer G, Ewert MK, Hephata K (1995) Selegeline hydrochloride treatment in narcolepsy. A double-blind, placebo-controlled study. Clin Neuropharmacol 18:306–319PubMedCrossRef

Nishida K, Itoh S, Inoue N, Kudo K, Ikeda N (2006) High-performance liquid chromatographic-mass spectrometric determination of methamphetamine and amphetamine enantiomers, desmethylselegiline and selegiline, in hair samples of long-term methamphetamine abusers or selegiline users. J Anal Toxicol 30:232–237PubMed

Pollo A, Benedetti F (2009) The placebo response: neurobiological and clinical issues of neurological relevance. Prog Brain Res 175:283–294PubMedCrossRef

Przuntek H, Bittkau S, Bliesath H, Buttner U, Fuchs G, Glass J, Haller H, Klockgether T, Kraus P, Lachenmayer L, Müller D, Müller T, Rathay B, Sgonina J, Steinijans V, Teshmar E, Ulm G, Volc D (2002) Budipine provides additional benefit in patients with Parkinson disease receiving a stable optimum dopaminergic drug regimen. Arch Neurol 59:803–806PubMedCrossRef

Rascol O, Brooks DJ, Melamed E, Oertel W, Poewe W, Stocchi F, Tolosa E (2005) Rasagiline as an adjunct to levodopa in patients with Parkinson’s disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 365:947–954PubMedCrossRef

Reinish LW, MacFarlane JG, Sandor P, Shapiro CM (1995) REM changes in narcolepsy with selegiline. Sleep 18:362–367PubMed

Roca J, Fuentes LJ, Marotta A, Lopez-Ramon MF, Castro C, Lupianez J, Martella D (2012) The effects of sleep deprivation on the attentional functions and vigilance. Acta Psychol (Amst) 140:164–176CrossRef

Roselaar SE, Langdon N, Lock CB, Jenner P, Parkes JD (1987) Selegiline in narcolepsy. Sleep 10:491–495PubMed

Shoulson I, Oakes D, Fahn S, Lang A, Langston JW, LeWitt P, Olanow CW, Penney JB, Tanner C, Kieburtz K, Rudolph A (2002) Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson’s disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann Neurol 51:604–612PubMedCrossRef

Siu EC, Tyndale RF (2008) Selegiline is a mechanism-based inactivator of CYP2A6 inhibiting nicotine metabolism in humans and mice. J Pharmacol Exp Ther 324:992–999PubMedCrossRef

Taylor DJ (2008) Insomnia and depression. Sleep 31:447–448PubMed

Taylor DJ, Lichstein KL, Durrence HH (2003) Insomnia as a health risk factor. Behav Sleep Med 1:227–247PubMedCrossRef

Thorpy M (2007) Therapeutic advances in narcolepsy. Sleep Med 8:427–440PubMedCrossRef

Trenkwalder C, Kies B, Rudzinska M, Fine J, Nikl J, Honczarenko K, Dioszeghy P, Hill D, Anderson T, Myllyla V, Kassubek J, Steiger M, Zucconi M, Tolosa E, Poewe W, Surmann E, Whitesides J, Boroojerdi B, Chaudhuri KR (2010) Rotigotine effects on early morning motor function and sleep in Parkinson’s disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord 26:90–99PubMedCrossRef

Verhagen ML, Del DP, van den MP, Fang J, Mouradian MM, Chase TN (1998) Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson’s disease. Neurol 50:1323–1326CrossRef

Waters CH, Sethi KD, Hauser RA, Molho E, Bertoni JM (2004) Zydis selegiline reduces off time in Parkinson’s disease patients with motor fluctuations: a 3 month, randomized, placebo-controlled study. Mov Disord 19:426–432PubMedCrossRef

Title: Switch from selegiline to rasagiline is beneficial in patients with Parkinson’s disease
Authors: Thomas Müller
Josef A. Hoffmann
Walter Dimpfel
Christian Oehlwein
Publication date: 01-05-2013
Publisher: Springer Vienna
Published in: Journal of Neural Transmission / Issue 5/2013
Print ISSN: 0300-9564
Electronic ISSN: 1435-1463
DOI: https://doi.org/10.1007/s00702-012-0927-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Switch from selegiline to rasagiline is beneficial in patients with Parkinson’s disease

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2013

Behavioral daily rhythmic activity pattern of adolescent female rat is modulated by acute and chronic cocaine

Genetic risk score predicting accelerated progression from mild cognitive impairment to Alzheimer’s disease

Neuroprotective effect of (–)-epigallocatechin-3-gallate in rats when administered pre- or post-traumatic brain injury

The dynactin p150 subunit: cell biology studies of sequence changes found in ALS/MND and Parkinsonian Syndromes

Differential effects of environmental enrichment and isolation housing on the hormonal and neurochemical responses to stress in the prefrontal cortex of the adult rat: relationship to working and emotional memories

Repetitive transcranial magnetic stimulation combined with cognitive training is a safe and effective modality for the treatment of Alzheimer’s disease: a randomized, double-blind study